Multiple sclerosis management during the COVID-19 pandemicBrandon Moss, Kathryn C. Fitzgerald, Kedar Mahajan et al.|Multiple Sclerosis Journal|2020Cited by 76
Use of a Smartphone to Gather Parkinson’s Disease Neurological Vital Signs during the COVID-19 PandemicJay L. Alberts, Anson B. Rosenfeldt, Mandy Miller Koop et al.|Parkinson s Disease|2021Cited by 20
A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)Giancarlo Comi, Catherine Lubetzki, Roland Henry et al.|Neurology|2022Cited by 5
A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)Ralph Benedict, Helmut Butzkeuven, Maria Pia Sormani et al.|Neurology|2022Cited by 4
A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosisXiaotong Jiang, Christian Barro, Marisa McGinley et al.|Multiple Sclerosis Journal|2024Cited by 1